Search
Stifel's Head of Therapeutics Research Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events
He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne. Coverage brought to you by
Nov 11
Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile.
CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile. Coverage brought to you by
Nov 11
Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins
Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.
Nov 10
Allucent’s new Chief Operating Officer, Patrick Phillips, discusses why choosing the right CRO is essential for small and mid-size biopharma companies
He highlights Allucent’s specialized expertise, global presence in more than 60 countries, and innovative application of AI to advance clinical development and improve operational efficiency. #sponsored
Nov 10
BioVenture VoiCes Episode 28: Hatteras Venture Partners' Clay Thorp
Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders. Chapters Early life end education – 3:31 Helping his brother run a genomics company - 10:28 Creating a seed fund – 16:50 North Carolina's strengths – 25:51 Bob Ingram – 29:56 Investing local and beyond – 4
Nov 10
Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.
Nov 8
Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1
CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.
Nov 8
Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.
Nov 8
Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC
Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.
Nov 7
Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
Nov 7
Science Explainer: Brain shuttle technologies have been in the news a lot lately. Natalie Ricciardi explains what you need to know about 1st and 2nd generation technologies in development.
She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.
Nov 7
Miami Oncology Summit: TuHURA Biosciences is trying to overcome resistance to cancer immunotherapies by trying to make tumors look like bacterium
Biotech veteran James Bianco, discusses his new Tampa based company, which is already in a trial designed to read out for potentially both accelerated and full approval. Coverage brought to you by
Nov 6
Miami Oncology Summit: Medical Oncologist Dionysios Watson discusses the latest in lung and head & neck cancer, and his early stage research on next-gen immunotherapy
He describes the need to target immunotherapy better by getting it right to the tumor sites, and modulating the tumor microenvironment. Coverage brought to you by
Nov 6
Miami Oncology Summit: Damian Green, Chief of Sylvester's Division of Transplantation and Cellular Therapy, discusses the latest in CAR-T and radiopharma
He weighs in on key issues like solid tumors, allo, and in vivo CAR-T. Plus, alpha vs beta emitters in the radiopharma space. Coverage brought to you by
Nov 6
Miami Oncology Summit: Thoracic Medical Oncologist Estelamari Rodriguez discusses the latest in lung cancer treatments
She covers KRAS, ROS1, EGFR, and more. Coverage brought to you by
Nov 6
Miami Oncology Summit: University of Miami Sylvester Comprehensive Cancer Center Director Stephen Nimer discusses the clinical and non-clinical research happening here today
He highlights Sylvester's NCI status and discusses how the institution is trying to contribute to diversity in clinical trials. Coverage brought to you by
Nov 6
Miami Oncology Summit: Oppenheimer Analyst Matthew Biegler discusses the breast cancer space and comments on key names
He discusses Celcuity, Relay, Olema, and more Coverage brought to you by
Nov 6
Miami Oncology Summit: Breast Cancer Oncologist Elisa Krill-Jackson discusses the latest in breast cancer including ADCs, doublets, triplets, and more
She explains how new therapies are keeping more patients off IV chemotherapy. Coverage brought to you by
Nov 6
Miami Oncology Summit: Oppenheimer's Head of Healthcare Investment Banking Michael Margolis discusses the funding environment and whether IPOs will pick back up
He says that the sector is much stronger than it was just months ago. Coverage brought to you by
Nov 6
Menlo Ventures published a report showing that the healthcare industry is the leading adopter of AI - one of the co-authors shares key takeaways
Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages. Medical documentation, billing and scribing are the biggest areas of adoption today, while patient engagement and the post acute relationship are emerging as next to be impacted.
Nov 5
.png){kind=logo}
